<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00413595</url>
  </required_header>
  <id_info>
    <org_study_id>II PV04/2006</org_study_id>
    <nct_id>NCT00413595</nct_id>
  </id_info>
  <brief_title>Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation</brief_title>
  <acronym>sifap2</acronym>
  <official_title>Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation in Young Patients With Fabry Disease: An Epidemiological, International, Multicenter Prognosis Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centogene AG Rostock</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shire Human Genetic Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centogene AG Rostock</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      New studies indicate that in about 1 - 2 percent of the younger stroke patients the cause
      could have been an undiagnosed genetic disease, the so called Fabry disease. In this case
      certain fat molecules are not digested and broken down by the body - but remain in the cells.
      These fat molecules build up to dangerous levels, which start to damage the body, because
      they accumulate e.g. in the walls of the blood vessels. This accumulation in the blood
      vessels of the whole body may cause life-threatening malfunctions in the brain, inducing a
      stroke.

      The purpose of this study is to investigate the stroke rehabilitation of Fabry patients
      during different therapeutic standard approaches for stroke and for Fabry disease (if any).
      During this study, stroke patients with Fabry disease will be monitored in greater detail to
      determine whether the differences in treatment are significant for patient recovery and on
      what they depend.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a group of young stroke patients with diagnosed Fabry disease the stroke rehabilitation
      will be investigated during different prophylactic therapeutic approaches. In this study the
      investigator will not be given any instructions on stroke and Fabry therapy.

      All patients with any etiology of stroke and a diagnosed Fabry disease submitted to the
      stroke unit of the participating centres which commit to work with the EUSI (European Stroke
      Initiative) recommendations for stroke management and diagnosis will be included into the
      study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2007</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the relapse rate of acute cerebrovascular events with clinical relevance in patients with different prophylactic approaches</measure>
    <time_frame>54 months study duration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life measured with the SF-36</measure>
    <time_frame>54 months study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of acute CVEs without clinical significance but with obvious signs in MRI diagnosis</measure>
    <time_frame>54 months study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory II (BDI II)</measure>
    <time_frame>54 months study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI)</measure>
    <time_frame>54 months study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rostocker Kopfschmerzfragen-Komplex (RoKoKo) (only in Austria and Germany)</measure>
    <time_frame>54 months study period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Habi test (only in Austrian and German centers)</measure>
    <time_frame>54 months study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trail Making Test (TMT)</measure>
    <time_frame>54 months study duration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional neurological deficits measured by the Mini Mental State Examination (MMSE)</measure>
    <time_frame>54 months study duration</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Fabry Disease</condition>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <description>Adult patients (18 - 55 years of age) with an acute cerebrovascular event of any etiology and the genetic diagnosis (a-galactosidase defect) of Fabry disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.</description>
    <arm_group_label>Observation</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      EDTA-blood and urine sample for central laboratory analysis of agalsidase antibodies and Gb3
      for safety issues.

      There will be a proteomic analysis in blood to check whether there will be the possibility to
      characterize a biomarker for Fabry disease.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (18 - 55 years of age) with an acute cerebrovascular event (CVE) of any
        etiology defined as patients having an ischemic stroke or transient ischemic attack and
        genetic diagnosis (a-galactosidase defect) of Fabry disease.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients (18 - 55 years of age) with an acute cerebrovascular event (CVE) of any
             etiology defined as patients having an ischemic stroke or transient ischemic attack

          -  Genetic diagnosis (a-galactosidase defect)of Fabry disease

          -  Written informed consent from patient

        Exclusion Criteria:

          -  No proven Fabry disease

          -  Participating in an other clinical trial with any investigational new drug or medical
             device

          -  Contraindication to any of the diagnostic procedures like e.g. MRI investigation

          -  Patient has been pretreated with Enzyme Replacement Therapy at the date of informed
             consent of sifap2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arndt Rolfs, Prof., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum für Neurologie</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University Hospital Sestre Milosrdnice</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Neurologique de Lyon, Service d'urgences Neurovasculaires</name>
      <address>
        <city>Lyon</city>
        <zip>F-69003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, S. Khechinashvili University clinic of Tbilisi state medical university</name>
      <address>
        <city>Tbilisi</city>
        <zip>0179</zip>
        <country>Georgia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Klinikum Hohe Warte</name>
      <address>
        <city>Bayreuth</city>
        <zip>95445</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Benjamin Franklin, Dept. of Neurology</name>
      <address>
        <city>Berlin</city>
        <zip>D-12200</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Allgemeines Krankenhaus Celle</name>
      <address>
        <city>Celle</city>
        <zip>29223</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Klinikum Chemnitz gGmbH</name>
      <address>
        <city>Chemnitz</city>
        <zip>09131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heinrich-Heine-University Duesseldorf, Dept. of Neurology</name>
      <address>
        <city>Duesseldorf</city>
        <zip>D-40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Giessen-Marburg Dept. of Neurology</name>
      <address>
        <city>Giessen</city>
        <zip>D-35385</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universitaetsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universitaetsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, Universitaetsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Neurology, Ökumenisches Hainich Klinikum gGmbH</name>
      <address>
        <city>Mühlhausen</city>
        <zip>99974</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ludwig-Maximilians-University of Munich, Klinikum München-Großhadern, Dept. of Neurology</name>
      <address>
        <city>München</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Neurology, University Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm, Department of Neurology</name>
      <address>
        <city>Ulm</city>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Psychiatry and Neurology, Dept. of Neurology</name>
      <address>
        <city>Warsaw</city>
        <zip>02-957</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar de Lisboa Central, Servico de Neurologia</name>
      <address>
        <city>Lisboa</city>
        <zip>1150-199</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Croatia</country>
    <country>France</country>
    <country>Georgia</country>
    <country>Germany</country>
    <country>Poland</country>
    <country>Portugal</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>http://www.sifap.de</url>
    <description>Study homepage</description>
  </link>
  <reference>
    <citation>Rolfs A, Böttcher T, Zschiesche M, Morris P, Winchester B, Bauer P, Walter U, Mix E, Löhr M, Harzer K, Strauss U, Pahnke J, Grossmann A, Benecke R. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005 Nov 19;366(9499):1794-6. Erratum in: Lancet. 2006 Dec 23;368(9554):2210.</citation>
    <PMID>16298216</PMID>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 19, 2006</study_first_submitted>
  <study_first_submitted_qc>December 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 20, 2006</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centogene AG Rostock</investigator_affiliation>
    <investigator_full_name>Volha Skrahina</investigator_full_name>
    <investigator_title>Dr.</investigator_title>
  </responsible_party>
  <keyword>Cerebrovascular Accident</keyword>
  <keyword>Cerebrovascular Accident, Acute</keyword>
  <keyword>Fabry Disease</keyword>
  <keyword>Fabry's Disease</keyword>
  <keyword>Anderson-Fabry Disease</keyword>
  <keyword>CVA (Cerebrovascular Accident)</keyword>
  <keyword>Stroke, acute</keyword>
  <keyword>Cerebral Stroke</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

